
    
      The LEAP-DB study is an 8-week, multicenter, randomized, blinded study to evaluate the
      performance of EEG-based biomarkers in predicting treatment outcome. Study participants will
      be randomized in a 1:1 ratio to receive either duloxetine or bupropion and followed for 8
      weeks.
    
  